Ruxolitinib

Jun 17, 2019

Promedior Presents Positive Data from a Phase 2 Study of PRM-151 in Myelofibrosis Patients Failed/Ineligible for Ruxolitinib at the 24th European Hematology Association Annual Congress

Jun 05, 2019

Sierra Announces Momelotinib Granted FDA Fast Track Designation

Jun 04, 2019

Sierra Announces FDA Regulatory Clarity for Momelotinib & Design of the MOMENTUM Phase 3 Clinical Trial

Dec 03, 2018

Sierra Oncology Reports Robust Transfusion Independence Rates in Transfusion Dependent Myelofibrosis Patients Treated with Momelotinib

Jun 13, 2018

Samus Therapeutics Announces PU-H71 Granted Orphan Drug Designation and First Patient Dosed in Phase 1b Study in Myelofibrosis

Mar 29, 2018

Global Cancer Janus Kinase Inhibitors Market Opportunity & Clinical Trial Insight 2023

Mar 09, 2018

CTI BioPharma Announces Publication of Pacritinib Phase 3 PERSIST-2 Clinical Trial in JAMA Oncology

Oct 26, 2017

Global Cancer Janus Kinase Inhibitors Market Opportunity & Clinical Trial Insight 2023

Aug 01, 2017

CTI BioPharma Announces First Patient Enrolled in Phase 2 Trial of Pacritinib in Patients with Myelofibrosis who have Thrombocytopenia and who have been Previously Treated with Ruxolitinib